High-Throughput, Low-Cost Detection of SARS-CoV-2 and Dominant SARS-CoV-2 Variants
The SARS-CoV-2 pandemic has created an enormous challenge for laboratories and communities worldwide. Currently, laboratories require cost-effective and rapid solutions to track the key SARS-CoV-2 variants currently in circulation, globally. While sequencing-based technologies are commonly used, they are highly complex, expensive, and have a long turnaround time.
To meet these challenges, Agena Bioscience® has developed the MassARRAY® SARS-CoV-2 Variant Panel (RUO), the MassARRAY SARS-CoV-2 Panel (EUA, CE-IVD), and the MassARRAY SARS-CoV-2/Flu Panel (RUO). These panels enable accurate, high-throughput, and low-cost detection of SARS-CoV-2, dominant SARS-CoV-2 variants, and influenza RNA.
The MassARRAY SARS-CoV-2 Variant Panel is available for Research Use Only.
The MassARRAY SARS-CoV-2 Panel is available for in vitro diagnostic use under Emergency Use Authorization (EUA) from the U.S. FDA and is CE-IVD marked in Europe.
The MassARRAY SARS-CoV-2/Flu Panel is available for Research Use Only.
High-throughput detection and differentiation of key SARS-CoV-2 variants.Learn More
For in vitro diagnostic use under EUA. CE-IVD marked in Europe.Learn More
High-throughput detection of SARS-CoV-2, Influenza A, and Influenza B RNA.Learn More
Article: Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Mass SpectrometryMore
Press: Agena Bioscience Signs Exclusive Distribution Agreement with AGBL Group of CompaniesMore
Press: Agena Bioscience Granted EUA for High-Throughput, Low-Cost SARS-CoV-2 PanelMore
Don’t see what you need here?
Assays by Agena scientists design, develop and functionally verify custom research use assays. Assays can be developed for targeted germline or somatic genotyping, translocations, copy number variants and methylation profiling.
Explore customer stories about rapid validation and lab expansion